MAIA
MAIA Biotechnology, Inc.
NYSE AmericanUSDEQUITY
Healthcare
DELAYED
Sell
-48/100
Last price
1.19
▲ 0.01 (0.85%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.19
Prev close
1.18
Day high
1.21
Day low
1.18
Volume
227.16K
Market cap
$73.47M
P/E (TTM)
—
52W range
0.87 – 3.19
Day trading desk
Gap from prior close
+0.85%
Prior close 1.18
VWAP
1.19
-0.10% from price
Relative volume
0.83×
Normal
Session range
4.31%
1.16 – 1.21
Position in range
60%
Mid range
ATR (14D)
0.07
5.85% of price
Prior day high
1.21
PDH
Prior day low
1.17
PDL
Bid / ask spread
—
Quote not published
Session volume
451.13K
Avg 544.68K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+3.48%
+1.5%
1M
-9.85%
-11.0%
3M
-19.05%
-23.6%
6M
-0.83%
-19.0%
YTD
-22.22%
-36.5%
1Y
-31.21%
-47.6%
3Y
-45.91%
-128.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on MAIA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
8.76M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 14, 26 | VITOC VLAD Chief Executive Officer |
BUY | 73.00K | $100.01K | Direct |
| Sep 10, 26 | GUERRERO RAMIRO Director |
BUY | 37.59K | $49.52K | Direct |
| Aug 28, 26 | GUERRERO RAMIRO Director |
BUY | 133.79K | $184.10K | Direct |
| Aug 24, 26 | GUERRERO RAMIRO Director |
BUY | 1.79K | $2.39K | Direct |
| Aug 20, 26 | GUERRERO RAMIRO Director |
BUY | 11.90K | $16.30K | Direct |
| Jun 1, 26 | GRYAZNOV SERGEI M. Officer |
BUY | 2.00K | $2.69K | Direct |
| Jun 1, 26 | SMITH STAN V Director |
BUY | 75.00K | $100.20K | Indirect |
| Jun 1, 26 | VITOC VLAD Chief Executive Officer |
BUY | 72.70K | $100.89K | Direct |
| Dec 22, 25 | CHAOUKI STEVEN M Director |
BUY | 40.85K | $50.00K | Direct |
| Dec 22, 25 | SMITH STAN V Director |
BUY | 57.19K | $70.00K | Indirect |
| Dec 22, 25 | LOUIE NGAR YEE Director |
BUY | 81.70K | $100.00K | Direct |
| Dec 5, 25 | SMITH STAN V Director |
BUY | 13.74K | $16.44K | Indirect |
| Nov 28, 25 | LUPUT CRISTIAN Director |
BUY | 38.15K | $41.85K | Direct |
| Nov 28, 25 | VITOC VLAD Chief Executive Officer |
BUY | 72.00K | $79.85K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHAOUKI STEVEN M |
Director | 151.87K | Purchase |
GRYAZNOV SERGEI M. |
Officer | 46.51K | Purchase |
GUERRERO RAMIRO |
Director | 773.30K | Purchase |
LOUIE NGAR YEE |
Director | 1.25M | Purchase |
LUPUT CRISTIAN |
Director | 437.63K | Purchase |
SMITH STAN V |
Director | — | Purchase |
VITOC VLAD |
Chief Executive Officer | 1.26M | Purchase |
Fundamentals
Market cap$73.47M
Enterprise value$44.79M
Revenue (TTM)—
Gross profit—
EBITDA—
Net income$-26.85M
EPS (TTM)$-0.62
Free cash flow$-13.79M
Total cash$27.60M
Total debt$0
Book value / share$0.34
Shares outstanding61.74M
Float55.30M
Short % of float3.76%
Dividend yield0.00%
Beta (5Y)0.28
Valuation & profitability ratios
Trailing P/E—
Forward P/E1.07
PEG ratio—
Price / sales—
Price / book3.50
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-218.68%
Return on assets-92.10%
Debt / equity—
Current ratio4.51
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $14.55M | $10.01M | $11.11M | $8.93M | +45.3% |
| Selling, general & admin | $9.72M | $6.95M | $9.07M | $6.14M | +39.9% |
| Total operating expense | $23.91M | $16.88M | $20.01M | $15.86M | +41.7% |
| Operating income | -$23.91M | -$16.88M | -$20.01M | -$15.86M | -41.7% |
| Net interest income | $313.95K | $318.31K | $27.63K | -$5.10K | -1.4% |
| Pre-tax income | -$22.40M | -$23.25M | -$19.77M | -$15.77M | +3.7% |
| Net income | -$22.40M | -$23.25M | -$19.77M | -$15.77M | +3.7% |
| Net income to common | -$22.40M | -$23.25M | -$19.77M | -$16.22M | +3.7% |
| Basic EPS | -0.70 | -1.05 | -1.49 | -1.75 | +33.3% |
| Diluted EPS | -0.70 | -1.05 | -1.49 | -1.75 | +33.3% |
| EBIT | -$22.40M | -$23.25M | -$19.77M | -$15.76M | +3.7% |
| EBITDA | -$22.40M | -$23.25M | -$19.77M | -$15.76M | +3.7% |
| Basic shares | 32.11M | 22.20M | 13.26M | 9.28M | +44.7% |
| Diluted shares | 32.11M | 22.20M | 13.26M | 9.28M | +44.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $8.66M | $9.60M | $7.15M | $10.95M | -9.8% |
| Cash & short-term investments | $8.66M | $9.60M | $7.15M | $10.95M | -9.8% |
| Total current assets | $9.70M | $10.15M | $7.56M | $11.81M | -4.4% |
| Total assets | $9.70M | $10.16M | $7.57M | $12.02M | -4.4% |
| Total current liabilities | $5.84M | $3.83M | $4.94M | $3.27M | +52.4% |
| Total liabilities | $7.33M | $6.52M | $7.09M | $3.51M | +12.4% |
| Retained earnings | -$109.63M | -$87.23M | -$63.98M | -$44.21M | -25.7% |
| Shareholder equity | $2.38M | $3.63M | $477.51K | $8.51M | -34.6% |
| Working capital | $3.87M | $6.32M | $2.63M | $8.54M | -38.9% |
| Net tangible assets | $2.38M | $3.63M | $477.51K | $8.51M | -34.6% |
| Shares issued | 38.62M | 26.16M | 16.99M | 10.96M | +47.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$22.40M | -$23.25M | -$19.77M | -$15.77M | +3.7% |
| Stock-based compensation | $2.63M | $1.91M | $3.09M | $2.32M | +37.6% |
| Change in working capital | $1.50M | -$1.24M | $3.09M | $352.78K | +221.1% |
| Operating cash flow | -$18.84M | -$15.70M | -$13.07M | -$12.10M | -20.0% |
| Financing cash flow | $17.91M | $18.18M | $9.27M | $12.48M | -1.5% |
| Free cash flow | -$18.84M | -$15.70M | -$13.07M | -$12.10M | -20.0% |
| End cash position | $8.66M | $9.60M | $7.15M | $10.95M | -9.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $5.64M | $3.53M | $1.88M | $6.36M | $3.11M | — | +60.0% |
| Selling, general & admin | $2.68M | $3.42M | $2.44M | $3.00M | $2.06M | — | -21.8% |
| Total operating expense | $8.11M | $6.74M | $3.96M | $9.36M | $5.17M | — | +20.4% |
| Operating income | -$8.11M | -$6.74M | -$3.96M | -$9.36M | -$5.17M | — | -20.4% |
| Net interest income | $236.32K | $111.76K | $73.65K | $78.43K | $79.70K | — | +111.5% |
| Pre-tax income | -$7.94M | -$6.37M | -$3.63M | -$8.90M | -$5.35M | — | -24.7% |
| Net income | -$7.94M | -$6.37M | -$3.63M | -$8.90M | -$5.35M | — | -24.7% |
| Net income to common | -$7.94M | -$6.37M | -$3.63M | -$8.90M | -$5.35M | — | -24.7% |
| Basic EPS | -0.13 | -0.14 | — | -0.27 | -0.18 | -0.16 | +7.1% |
| Diluted EPS | -0.13 | -0.14 | — | -0.27 | -0.18 | -0.16 | +7.1% |
| EBIT | -$8.11M | -$6.74M | -$3.63M | -$8.90M | -$5.17M | — | -20.4% |
| EBITDA | -$8.11M | -$6.74M | -$3.63M | -$8.90M | -$5.17M | — | -20.4% |
| Basic shares | 60.79M | 45.21M | — | 33.20M | 30.30M | 27.70M | +34.5% |
| Diluted shares | 60.79M | 45.21M | — | 33.20M | 30.30M | 27.70M | +34.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $27.60M | $34.41M | $8.66M | $10.89M | $10.14M | -19.8% |
| Cash & short-term investments | $27.60M | $34.41M | $8.66M | $10.89M | $10.14M | -19.8% |
| Total current assets | $28.24M | $35.32M | $9.70M | $11.75M | $11.04M | -20.0% |
| Total assets | $28.24M | $35.32M | $9.70M | $11.78M | $11.05M | -20.1% |
| Total current liabilities | $6.26M | $6.32M | $5.84M | $9.99M | $5.04M | -1.0% |
| Total liabilities | $7.57M | $7.56M | $7.33M | $11.74M | $7.17M | +0.1% |
| Retained earnings | -$123.94M | -$116.00M | -$109.63M | -$106.00M | -$97.10M | -6.8% |
| Shareholder equity | $20.68M | $27.76M | $2.38M | $41.67K | $3.88M | -25.5% |
| Working capital | $21.98M | $28.99M | $3.87M | $1.76M | $6.00M | -24.2% |
| Net tangible assets | $20.68M | $27.76M | $2.38M | $41.67K | $3.88M | -25.5% |
| Shares issued | 60.82M | 60.67M | 38.62M | 34.45M | 31.82M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$7.94M | -$6.37M | -$3.63M | -$8.90M | -$5.35M | -24.7% |
| Stock-based compensation | $723.91K | $650.02K | $810.80K | $646.90K | $802.48K | +11.4% |
| Change in working capital | $200.85K | $619.60K | -$4.32M | $4.96M | $86.22K | -67.6% |
| Operating cash flow | -$6.75M | -$5.31M | -$7.02M | -$3.49M | -$4.14M | -27.1% |
| Financing cash flow | -$65.00K | $31.05M | $4.80M | $4.23M | $3.41M | -100.2% |
| Free cash flow | -$6.75M | -$5.31M | -$7.02M | -$3.49M | -$4.14M | -27.1% |
| End cash position | $27.60M | $34.41M | $8.66M | $10.89M | $10.14M | -19.8% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.11 | -0.13 | -18.2% |
| Mar 2026 | -0.18 | -0.14 | +22.2% |
| Dec 2025 | -0.13 | -0.14 | -5.2% |
| Sep 2025 | -0.19 | -0.27 | -42.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.13 | 1 | $0 | 0.0% |
| Next quarter | -0.14 | 1 | $0 | 0.0% |
| Current year | -0.54 | 1 | $0 | 0.0% |
| Next year | 1.11 | 2 | $0 | 0.0% |
Analyst targets & ownership
Mean target$12.00
High target$14.00
Low target$10.00
Implied upside908.40%
Analyst count2
ConsensusSTRONG BUY
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders14.41%
Held by institutions21.91%
Institutions holding38
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.20
-0.92% from price
SMA 20
1.27
-6.63% from price
SMA 50
1.32
-9.82% from price
SMA 100
1.34
-11.01% from price
SMA 200
1.49
-20.17% from price
EMA 12
1.22
-2.48% from price
EMA 26
1.27
-6.08% from price
EMA 50
1.30
-8.66% from price
RSI (14)
40.0
Neutral
MACD (12,26,9)
-0.05
Hist -0.01
ATR (14)
0.07
5.85% of price
Realised vol 30D
49.3%
Annualised
Bollinger upper
1.44
20, 2σ
Bollinger lower
1.11
20, 2σ
50 / 200 cross
Death
1.32 vs 1.49
Trend bias
Below 200
-20.17%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.71
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
49.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-61.0%
Peak to trough
Max drawdown 5Y
-89.4%
Peak to trough
ATR 14
0.07
5.85% of price
Beta (reported)
0.28
5Y monthly, from filing
Short interest
Shares short
2.10M
Prior 2.75M
Change vs prior
-23.6%
Shorts covering
% of float
3.76%
Normal
% of shares out
3.45%
Against total outstanding
Days to cover
4.5
Liquid
Float
55.30M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 21, 23 | Noble Capital Markets | INITIATED | — | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-06
Offering Registrations
S-3 · 2026-09-25
Offering Registrations
S-3 · 2026-08-21
Periodic Financial Reports
10-Q · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-05-22
Proxy Statements
DEFA14A · 2026-05-19
Periodic Financial Reports
10-Q · 2026-05-11
Proxy Statements
DEFA14A · 2026-04-27
Headlines
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
GlobeNewswire · 6d ago
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
GlobeNewswire · 14d ago
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
GlobeNewswire · 15d ago
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
GlobeNewswire · 21d ago
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
GlobeNewswire · 22d ago
MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
GlobeNewswire · 27d ago
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
GlobeNewswire · 51d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.